Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$AKTX a steal at the current pps. Lots going on including Covid medications.
$AKTX NEW YORK and LONDON, May 29, 2020 (GLOBE NEWSWIRE)
-- Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced financial results for the first quarter ended March 31, 2020,
as well as recent clinical progress.
“We remain focused on our mission of addressing severe inflammatory diseases with significant unmet medical need.
We are pleased that our company is now in the process of planning or undertaking pivotal trials in both BP and HSCT-TMA as well as progressing next clinical steps for studies in atopic keratoconjunctivitis (AKC) and COVID-19 pneumonia,” said Clive Richardson, Chief Executive Officer of Akari Therapeutics.
Severe inflammatory diseases remain an area of high unmet need.
Akari continues to make progress driving its anti-inflammatory programs forward, including the recent announcement of positive topline results from our Phase II BP study in May.
$AKTX ]Open pivotal study in pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) with orphan and fast track approval
Preparing for pivotal study in bullous pemphigoid (BP) following recent completion of successful Phase II study
Positive EMA opinion on orphan designation for nomacopan for BP along with Orphan Drug designation granted by FDA in BP
https://finance.yahoo.com/news/akari-therapeutics-reports-first-quarter-110010702.html
$AKTX COULD GO BONKERS !!!!!
$AKTX $30MIL AH LOT DOE RE ME, RE;AKTX News: Akari Therapeutics Enters into a Securities Purchase Agreement for up to $30 Million with Aspire Capital Fund, LLC 07/01/2020 09:16:10 AM
AKTX News: Akari Therapeutics Announces Appointment of Chief Financial Officer 07/01/2020 09:15:10 AM
AKTX News: Report of Foreign Issuer (6-k) 06/01/2020 08:34:18 AM
AKTX News: Akari Therapeutics Enters into a Securities Purchase Agreement for up to $30 Million with Aspire Capital Fund, LLC 07/01/2020 09:16:10 AM
$AKTX Securities Registration (foreign Private Issuer) (f-1) Edgar (US Regulatory) - 7/17/2020 4:27:37 PM
$AKTX Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/1/2020 9:23:33 AM
Akari Therapeutics Enters into a Securities Purchase Agreement for up to $30 Million with Aspire Capital Fund, LLC GlobeNewswire Inc. - 7/1/2020 9:16:10 AM
$AKTX Akari Therapeutics Announces Appointment of Chief Financial Officer GlobeNewswire Inc. - 7/1/2020 9:15:10 AM
$AKTX Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/1/2020 8:34:18 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/29/2020 7:31:03 AM
$AKTX PPS COULD BLOSSUM @ ANYTIME !!!!!
$AKTX VIRUS PLAY WITH OTHER STUFF IN PHASE-3
Haven’t sold anything on my end. Holding 4,000 and patiently waiting. Catalyst and we fly!
$AKTX
Been adding every day. Got bigly position here. Ready for good news $AKTX
I’m ready. Bought in a bit higher and have been averaging down since. I also believe this will go north hard!
$AKTX
Who’s in before the big move? Trading at $2 $AKTX
AKTX NEWS this morning positive preclinical trials and has a history of big jumps from $2 - $10 overnight. Check out the 1 year chart
https://www.stockscores.com/charts/charts/?ticker=aktx
Should AKTX push nomacopan to market, the potential here would be incredible. There are no approved treatments that are indicated for HSCT-TMA patients. However, the market surrounding the condition is a massive one.
In fact, experts expect that the HSCT-TMA market will grow to be worth well over $37 billion annually by the year 2025. That’s a big deal, especially when you consider that Akari Therapeutics is currently trading with a sub-$50 million market cap.
With no competition on the playing field, this relatively small biotech company could have a blockbuster on its hands, should the treatment be approved. So, keep your eyes peeled as this opportunity could be huge.
* * $AKTX Video Chart 01-10-2020 * *
Link to Video - click here to watch the technical chart video
* * $AKTX Video Chart 12-02-2019 * *
Link to Video - click here to watch the technical chart video
AKTX nice 6k now
Alot of mm's showed up. Is there some bigger news coming out?
News out. Orphan drug designation by the FDA. Looking for minimum $4.00 tomorrow.
AKTX got orphan drug designation...out just now!!
Where do we see this heading? I’m in around $2 from a little bit ago... but I feel like I don’t understand the full meaning and applications of today’s approval - any help?
AKTX!! Oh SOOOOOO sweet!! PATIENCE PAYS$$$$$$MBD
AKTX..Does she have legs to get back to the 52wk high!!?? Let's see over the next few days how the MM'$ Feel! LMAO!!
Today is Friday they're probably gonna try to hold it down as much as possible until Tuesday imo!! MBD
AKTX, Been very good to me. MBD
AKTX!! PRAISE GOD!! MBD
AKTX!! YES Love these mornings when I WAKE UP to the smell of $$$$$..MBD
Fast Track + Orphan Drug designation = $$$
AKTX!! YESSS, Run baby!! Next TENX!! My motto . PATIENCE PAYS!!! MBD
Akari Therapeutics PLC (NASDAQ: AKTX) disclosed that the FDA granted Orphan Drug Designation to the company for Nomacopan.
https://m.benzinga.com/article/14355179?utm_referrer=https%3A%2F%2Fwww.google.com%2F&utm_source=https%3A%2F%2Fwww.google.com%2F
* * $AKTX Video Chart 08-29-2019 * *
Link to Video - click here to watch the technical chart video
Congrats, you was right and I hold a bag at 2,20. What is next you expect?
Yep ...
Days range $1.66-1.74
... last week
* * $AKTX Video Chart 08-14-2019 * *
Link to Video - click here to watch the technical chart video
Followers
|
13
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
552
|
Created
|
09/21/15
|
Type
|
Free
|
Moderators |
Akari is focused on developing inhibitors of acute and chronic inflammation, specifically the complement system, and leukotriene system,
for the treatment of rare and orphan diseases with unmet need. We believe that blocking early mediators of inflammation
will prevent initiation and continual amplification of the processes that cause certain diseases.
Nomacopan is a recombinant small protein (16,740 Da) that acts on complement component-C5,
preventing release of C5a and formation of C5b–9 (also known as the membrane attack complex, or MAC),
and independently also inhibits leukotriene B4, or LTB4, activity, both elements that are co-located as part of the immune/inflammatory response.
Nomacopan is currently being clinically evaluated in four indications:
Akari believes that the dual action of nomacopan on both C5 and LTB4 may be beneficial in AKC, BP, and aHUS. Akari is also developing other tick derived proteins, including longer acting versions.
Nomacopan is a highly soluble and stable biological molecule, and independently binds to both C5 and LTB4. This novel dual binding enables targeting of two distinct and separate disease categories based on their underlying etiology.
July 1, 2020
July 1, 2020
June 1, 2020
May 1, 2020
March 31, 2020
Patients with COVID-19 pneumonia
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |